Skip to content
Kineret(anakinra)
Kineret (anakinra) is a protein pharmaceutical. Anakinra was first approved as Kineret on 2001-11-14. It is used to treat cryopyrin-associated periodic syndromes and rheumatoid arthritis in the USA. It has been approved in Europe to treat rheumatoid arthritis.
Download report
Favorite
COVID-19
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
musculoskeletal diseasesD009140
hereditary congenital and neonatal diseases and abnormalitiesD009358
skin and connective tissue diseasesD017437
immune system diseasesD007154
signs and symptoms pathological conditionsD013568
Trade Name
FDA
EMA
Kineret
Drug Products
FDA
EMA
Reference product - 351(a)
Reference product - 351(a)
Interchangeable product - 351(k)
Interchangeable product - 351(k)
Biosimilar product - 351(k)
Biosimilar product - 351(k)
Anakinra
Tradename
Proper name
Company
Number
Date
Products
KineretanakinraSwedish Orphan Biovitrum AB (publ)N-103950 RX2001-11-14
1 products
Labels
FDA
EMA
Brand Name
Status
Last Update
kineretBiologic Licensing Application2020-12-30
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
cryopyrin-associated periodic syndromes—D056587M04.2
rheumatoid arthritisEFO_0000685D001172M06.9
Agency Specific
FDA
EMA
Expiration
Code
anakinra, Kineret, Swedish Orphan Biovitrum AB (publ)
2027-12-18Orphan excl.
Patent Expiration
No data
ATC Codes
L: Antineoplastic and immunomodulating agents
— L04: Immunosuppressants
— L04A: Immunosuppressants
— L04AC: Interleukin inhibitors
— L04AC03: Anakinra
HCPCS
No data
Clinical
Clinical Trials
166 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Rheumatoid arthritisD001172EFO_0000685M06.9—313411
Type 2 diabetes mellitusD003924EFO_0001360E11—3—137
Knee injuriesD00771811—1—2
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Covid-19D000086382U07.1—76—113
Heart failureD006333EFO_0003144I50272—18
Cytokine release syndromeD000080424D89.83—42——5
Mucocutaneous lymph node syndromeD009080EFO_0004246M30.3221——4
Type 1 diabetes mellitusD003922EFO_0001359E10241——4
PneumoniaD011014EFO_0003106J18—23——3
Metabolic syndromeD024821EFO_0000195E88.81—12——3
Virus diseasesD014777B34—31——3
Juvenile arthritisD001171EFO_0002609M08—11—13
Chronic renal insufficiencyD051436N18—31——3
Show 19 more
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
InflammationD00724923——26
Multiple myelomaD009101C90.023———4
Macrophage activation syndromeD055501EFO_100180613———4
Chronic kidney failureD007676EFO_0003884N18.6—3——14
B-cell lymphomaD016393—3———3
AsthmaD001249EFO_0000270J4533———3
Pancreatic neoplasmsD010190EFO_0003860C2521———3
Large b-cell lymphoma diffuseD016403C83.3—2———2
Non-hodgkin lymphomaD008228C85.9—2———2
HypoglycemiaD007003HP_0001943E16.2—1——12
Show 36 more
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Healthy volunteers/patients—3————3
NeoplasmsD009369C802————2
Cryopyrin-associated periodic syndromesD056587M04.21———12
PainD010146EFO_0003843R521———12
Breast neoplasmsD001943EFO_0003869C501————1
B-cell chronic lymphocytic leukemiaD015451C91.11————1
Castration-resistant prostatic neoplasmsD0641291————1
Chronic granulomatous diseaseD006105EFO_0000338D711————1
EndometriosisD004715EFO_0001065N801————1
Pulmonary arterial hypertensionD0000810291————1
Show 6 more
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Bariatric surgeryD050110————11
Dumping syndromeD004377EFO_1001307K91.1————11
AdiposityD050154————11
Gestational diabetesD016640HP_0009800O24.4————11
Coronary artery diseaseD003324I25.1————11
Glucose intoleranceD018149HP_0000833R73.03————11
Respiratory insufficiencyD012131HP_0002093J96.9————11
Conversion disorderD003291F44————11
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameANAKINRA
INNanakinra
Description
Interleukin-1 receptor antagonist protein precursor (IL-1ra) (IRAP)
Classification
Protein
Drug classinterleukin receptor antagonists: interleukin-1 (IL-1) receptor antagonists
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)—
Identifiers
PDB—
CAS-ID143090-92-0
RxCUI72435
ChEMBL IDCHEMBL1201570
ChEBI ID—
PubChem CID—
DrugBankDB00026
UNII ID9013DUQ28K (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 13,573 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
6,914 adverse events reported
View more details